Claims for Patent: 12,377,104

Summary for Patent: 12,377,104

Title:	Methods for treating a fatty liver disease
Abstract:	The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH/improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH/improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.
Inventor(s):	Rebecca Taub, Dominic Labriola
Assignee:	Madrigal Pharmaceuticals Inc
Application Number:	US19/045,070
Patent Claims:	1. A method of treating nonalcoholic steatohepatitis (NASH), comprising: determining a weight of an adult human subject in need thereof, and based on determination of the weight of the adult human subject in need thereof, administering to the adult human subject in need thereof a solid oral dosage form comprising: (i) resmetirom or a pharmaceutically acceptable salt thereof at a dosage of 100 mg per day, if the adult human subject in need thereof is determined to weigh 100 kg or more; or (ii) resmetirom or the pharmaceutically acceptable salt thereof at a dosage of 80 mg per day, if the adult human subject in need thereof is determined to weigh less than 100 kg. 2. The method according to claim 1, wherein the adult human subject in need thereof is determined to weigh 100 kg or more and is administered the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof at the dosage of 100 mg per day. 3. The method according to claim 1, wherein the adult human subject in need thereof is determined to weigh less than 100 kg and is administered the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof at the dosage of 80 mg per day. 4. The method according to claim 1, wherein the solid oral dosage form is a tablet. 5. The method according to claim 4, wherein the solid oral dosage form comprises resmetirom. 6. The method according to claim 2, wherein the solid oral dosage form is a tablet. 7. The method according to claim 6, wherein the solid oral dosage form comprises resmetirom. 8. The method according to claim 3, wherein the solid oral dosage form is a tablet. 9. The method according to claim 8, wherein the solid oral dosage form comprises resmetirom. 10. A method of improving liver fibrosis comprising: determining a weight of an adult human subject in need thereof; and based on determination of the weight of the adult human subject in need thereof, administering to the adult human subject in need thereof a solid oral dosage form comprising: (i) resmetirom or a pharmaceutically acceptable salt thereof at a dosage of 100 mg per day, if the adult human subject in need thereof is determined to weigh 100 kg or more; or (ii) resmetirom or the pharmaceutically acceptable salt thereof at a dosage of 80 mg per day, if the adult human subject in need thereof is determined to weigh less than 100 kg; and wherein the adult human subject in need thereof has nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis consistent with stages F2 to F3. 11. The method according to claim 10, wherein the adult human subject in need thereof is determined to weigh 100 kg or more and is administered the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof at the dosage of 100 mg per day. 12. The method according to claim 10, wherein the adult human subject in need thereof is determined to weigh less than 100 kg and is administered the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof at the dosage of 80 mg per day. 13. The method according to claim 10, wherein the method is of improving the liver fibrosis by at least one stage in the adult human subject in need thereof. 14. The method according to claim 11, wherein the method is of improving the liver fibrosis by at least one stage in the adult human subject in need thereof. 15. The method according to claim 12, wherein the method is of improving the liver fibrosis by at least one stage in the adult human subject in need thereof. 16. The method according to claim 13, wherein the solid oral dosage form is a tablet. 17. The method according to claim 16, wherein the solid oral dosage form comprises resmetirom. 18. The method according to claim 14, wherein the solid oral dosage form is a tablet. 19. The method according to claim 18, wherein the solid oral dosage form comprises resmetirom. 20. The method according to claim 15, wherein the solid oral dosage form is a tablet. 21. The method according to claim 20, wherein the solid oral dosage form comprises resmetirom. 22. The method according to claim 13, wherein the adult human subject in need thereof has liver fibrosis characterized as fibrosis stage F3. 23. The method according to claim 14, wherein the adult human subject in need thereof has liver fibrosis characterized as fibrosis stage F3. 24. The method according to claim 15, wherein the adult human subject in need thereof has liver fibrosis characterized as fibrosis stage F3.